Quick Links PATIENT-CENTRIC SOLUTIONS Bioavailability Enhancement Improve solubility within the gastrointestinal tract Adare provides technologies to enable and improve the bioavailability of drugs with low solubility or an extreme pH-dependent solubility profile. The resulting formulations can offer effective oral dosing of poorly soluble drug candidates, equivalent therapy at lower doses, faster onset of action, and minimization of food effect. The bioavailability enhancement technologies provided by Adare include Diffucaps® solid solution or solid dispersion. How It Works A solid-solution/solid dispersion drug form is contained in layers of excipients and release-controlling polymers. This is combined with a crystallization inhibitor, enhancing bioavailability by maintaining the drug in its amorphous state. The solubility-enhanced beads can be coated with one or more functional polymers to achieve extended-release profiles suitable for once- or twice-daily dosing. Key Advantages Adjustable dosage strength and dissolution profile to achieve the desired in vivo pharmacokinetic profile Varied release profiles, active ingredients, or both—in one product Enhances drug solubility in sections of the gastrointestinal tract through combined use with other Adare technologies Reduces gastric mucosal irritation Available as a capsule, orally disintegrating tablet, rapidly disintegrating tablet, or as a sprinkle Minimizes food effect For more information on bioavailability enhancement technologies provided by Adare, review the Related Resources and speak with one of our experts today. RELATED RESOURCES PATIENT-CENTRIC SOLUTIONS Overview Taste Masking Customized Release Bioavailability Enhancement LATEST NEWS EVENTS Speak With An Expert Nathan Dormer Director, Drug Product Development Nathan Dormer, Ph.D. is the Director of Drug Product Development at Adare Pharma Solutions in Lenexa, KS. Dr. Dormer is a pharmaceutical scientist and bioengineer with over a decade of experience developing microsphere-based solid oral and parenteral/implantable dosage forms, with an emphasis on controlled release and other innovative formulation concepts. He is responsible for pharmaceutical development activities such as creation of prototypes, analytical method development, CMC and IP documentation, pharmacokinetic correlations, tech transfer, manufacture of clinical supplies, and commercial scale process optimization and validation. Dr. Dormer received his B.S. in Chemical Engineering and his Ph.D. with Honors in Bioengineering, both from The University of Kansas. Contact Me What question can I answer for you? LET ME KNOW HOW WE CAN HELP* Please be specific FIRST NAME* LAST NAME* COMPANY* EMAIL* PHONE* COUNTRY* Select country... United States Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darrussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo, Democratic Republic of the Congo, Republic of the Cook Islands Costa Rica Côte d'Ivoire Croatia Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini (Swaziland) Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Liechtenstein Lithuania Luxembourg Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestine, State of Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russia Rwanda Saint Barthélemy Saint Helena Saint Kitts and Nevis Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon Islands South Africa South Georgia South Korea South Sudan Spain Sri Lanka Suriname Svalbard and Jan Mayen Islands Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom Uruguay US Minor Outlying Islands Uzbekistan Vanuatu Venezuela Vietnam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe CORPORATE OFFICES Headquarters: Princeton Pike Corporate Center 1200 Lenox Drive, Suite 100 Lawrenceville, NJ 08648 USA +1 (609) 450-1312 597, Boul. Laurier Mont-Saint-Hilaire, QC Canada, J3H 6C4 +1 (450) 600-1414 MANUFACTURING Via Martin Luther King, 13 20060 Pessano con Bornago (MI) Italy +39 02 954281 Via Molise, 16 20098 San Giuliano Milanese (MI) Italy +39 02 988981-200 Route de Bû 78550 Houdan France +33 (0)1 30 46 19 00 DEVELOPMENT & MANUFACTURING 845 Center Drive Vandalia, Ohio 45377 USA +1 (937) 898-9669 8006 Reeder Street Lenexa, KS 66214 USA ©2021 Adare Pharma Solutions. All rights reserved Privacy Policy Terms & Conditions Contact Us